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Bermejo3,13, Yolanda cámara3,13, Ramon Martí3,13, Fabiola Mavillard7,8, Miguel A. Martin2,3, 
Julio Montoya3,14, Eduardo Ruiz-pesini3,14, Joan Villarroya15,16, Raquel Montero3,17, 
Francesc Villarroya15,16, Rafael Artuch3,17, Michio Hirano10, Andrés nascimento3,4 & 
Cecilia Jimenez-Mallebrera3,4,18 ✉
GDF-15 is a biomarker for mitochondrial diseases. We investigated the application of GDF-15 as 
biomarker of disease severity and response to deoxynucleoside treatment in patients with thymidine 
kinase 2 (TK2) deficiency and compared it to FGF-21. GDF-15 and FGF-21 were measured in serum 
from 24 patients with TK2 deficiency treated 1–49 months with oral deoxynucleosides. Patients were 
grouped according to age at treatment and biomarkers were analyzed at baseline and various time 
points after treatment initiation. GDF-15 was elevated on average 30-fold in children and 6-fold in 
adults before the start of treatment. There was a significant correlation between basal GDF-15 and 
severity based on pretreatment distance walked (6MWT) and weight (BMI). During treatment, GDF-
15 significantly declined, and the decrease was accompanied by relevant clinical improvements. The 
decline was greater in the paediatric group, which included the most severe patients and showed 
the greatest clinical benefit, than in the adult patients. The decline of FGF-21 was less prominent 
and consistent. GDF-15 is a potential biomarker of severity and of therapeutic response for patients 
with TK2 deficiency. In addition, we show evidence of clinical benefit of deoxynucleoside treatment, 
especially when treatment is initiated at an early age.
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Mitochondrial DNA depletion and deletion syndrome 2 (MTDPS2) is caused by mutations in the nuclear gene 
TK2 that encodes thymidine kinase 2 (TK2) which is necessary for mitochondrial DNA replication and mainte-
nance1. TK2 deficiency manifests predominantly as a myopathy and includes extremely severe and rapidly pro-
gressive early-onset forms with survival of less than two years, to milder forms with late or very late-onset, and a 
slower rate of progression, but with almost invariable respiratory involvement than shortens life expectancy2–4.
A new therapy for TK2 deficiency is under investigation, based on administration of oral deoxynucleosides. 
The rationale is to induce the synthesis of pyrimidine deoxynucleotides (dTTP and dCTP) via alternative enzyme 
pathways by means of supplementation with their precursors. Although some patients started with taking oral 
deoxynucleotides (dTMP and dCMP), after the demonstration in vitro and in vivo5,6 that deoxynucleosides are 
the active agents, the therapy was changed to deoxynucleosides (dThd and dCtd). The efficacy of oral deoxy-
nucleoside treatment was demonstrated in pre-clinical studies7,8 and in a group of 16 patients treated under a 
compassionate use program9. Without any major side effect, the therapy had striking effects on early-onset severe 
myopathy patients, such as improvement in muscle strength, reduction or discontinuation of mechanical ven-
tilation and gastrostomy feeding, and regaining the ability to walk. The patients also showed considerable func-
tional improvements according to motor outcome measures in childhood-onset cases and at least stabilization in 
late-onset ones9.
Biomarkers are playing an increasingly important role in drug development and treatment implementation10. 
In addition to contributing to a better understanding of diseases, biomarkers provide more sensitive and specific 
means of diagnosing and ways to determine responses to new treatments. In this way, they help to streamline 
clinical trial efficacy and reduce uncertainty in regulatory decision-making, thus accelerating drug approval and 
drug access for patients.
According to BEST (The Biomarkers, EndpointS and other Tools, FDA-NIH Biomarker Working Group, 
https://www.ncbi.nlm.nih.gov/books/NBK326791/) a monitoring biomarker is a biomarker which is measured 
serially for assessing the status of a disease or for evidence of an effect of a medical product. A pharmacodynam-
ics/response biomarker is used to show that a biological response has occurred in an individual who has been 
exposed to a medical product.
Growth Differentiation Factor 15 (GDF-15) is a cytokine that is induced in response to various stimuli and in 
different pathological situations where it is associated with disease progression and negative prognosis11–13. We 
previously demonstrated that GDF-15 is a valuable circulating diagnostic biomarker for mitochondrial diseases 
including mitochondrial DNA depletion and deletion syndromes, MELAS and KSS14–16. Fibroblast Growth Factor 
21 (FGF-21) has also been reported to be elevated in a range of mitochondrial diseases, particularly in those 
with muscle involvement17. Determination of circulating GDF-15 and FGF-21 has greatly aided the diagnosis of 
mitochondrial pathologies since their sensitivity is significantly higher than other conventional biomarkers such 
as venous lactate level16,18.
The objective of this study was to explore the application of circulating GDF-15 as a biomarker of disease 
severity and prognosis as well as to monitor response to deoxynucleosides treatment in patients with TK2 defi-
ciency, and compare it with FGF-21. Furthermore, since GDF-15 has been linked to inflammation in some dis-
eases13,19 we also investigated circulating levels of inflammatory cytokines.
Results
Patients. The 26 patients included span the spectrum of phenotypes associated with TK2 deficiency4. Pre-
treatment data are summarized in Table 1. Patients P25 and P26 had to stop treatment soon after initiation 
because of an increase in liver enzymes. They were not further analyzed. Follow-up data of P1 to P24 are available 
in Tables 2 and 3.
The 24 treated patients were grouped according to age at treatment initiation: group 1 (the paediatric group) 
started treatment before 16 years of age (P1 to P15), and group 2 (the adult group) started treatment after this 
age (P16 to P24). This grouping allowed us to compare GDF-15 and FGF-21 serum levels with aged-matched 
controls and takes into account the observation that age-related metabolic changes contribute to the efficacy of 
deoxynucleoside therapy8.
Group 1 consisted of 15 children (five female and ten male), six of them with early-onset and very rapid 
progression (P1, P3, P4, P5, P6, and P7) and nine with childhood-onset and an intermediate disease course (P2 
and P8-P15). Group 2 consisted of nine patients (seven female and two male) and included one patient with 
childhood-onset (P22) and eight patients with late-onset forms (P16 to P21 and P23 to P24). To assess disease 
progression, patients were compared with other patients with similar clinical phenotypes based on previous pub-
lications2,4,9. The follow-up time ranged from 1 to 49 months for patients in group 1 and from 1 to 46 months for 
patients in group 2. A summary of the age of onset and treatment initiation for each group is provided in Table 4.
Change of serum GDF-15 and FGF-21 over time in treated patients. We previously described the 
baseline levels of GDF-15 in a healthy pediatric population15. For the purposes of this study, we analyzed GDF-15 
serum levels in 13 adult healthy controls (age range 23–56 years) and found that the mean GDF-15 concentration 
was 323 pg/mL (SE 19.7; range 232–460 pg/mL) which is comparable to the mean values in the pediatric (age 
range 1 month to 18 years) control population (350 pg/mL; SE 20.7, range 155–584) and overlaps with values 
reported elsewhere20. Baseline levels were available from 12 participants in group 1 and nine in group 2. The mean 
values and ranges for GDF-15 and FGF-21 for both groups of patients are summarised in Table 4. GDF-15 levels 
were increased on average by 30-fold in group 1 (mean 10716 pg/mL; SE 2579; range 2641–27066), and by six-fold 
in group 2 (mean 1955 pg/mL; SE 149; range 1261–2483), relative to the mean values in the control groups. If we 
only take into account the five patients from group 1 with the most severe disease form for whom we have basal 
measurements, the average GDF-15 levels were 60-fold increased over the value in the paediatric control group 
(mean 20246 pg/mL; SE 2371; range 14756–27066).
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For FGF-21, average baseline levels were elevated by 25-fold in group 1 (mean 1981 pg/mL; SE 702; range 402–
731) and by six-fold in group 2 (mean 429 pg/mL; SE 106; range 179–943), relative to control values16. Similarly 
to GDF-15, the average basal FGF-21 value almost doubled if we only took into account the most severe patients 
from group 1 (Table 4).
Thus, both GDF-15 and FGF-21 basal serum levels are associated with the severity of the phenotype. This was, 
however, not the case for CK since its basal levels were comparable regardless of the severity of the phenotype 
(Fig. 1).
The development of serum GDF-15 values at different times after the initiation of treatment is represented 
in Fig. 1. We applied a linear mixed model using the log-transformed GDF-15 concentration levels and found 
a significant decrease over time in patients in both group 1 (p < 0.0001) and group 2 (p = 0.0082) (Fig. 2A,B). 
FGF-21 followed a similar trend, although not significant, for group 1 (p = 0.062) but this trend was not present 
in group 2 (Fig. 2C,D).
Because the time points at which GDF-15 levels were measured are not uniform across patients and to homog-
enize the data we grouped the measurements at regular intervals corresponding to the follow-up intervals for 
each group (Supp. Fig. 1). We observed that in group 1 GDF-15 values decreased steadily over time, particularly 
between 0 and 24 months and that the difference between intervals was statistically significant (Kruskal-Wallis 
chi-squared p < 0.001). After 12 months of treatment, most values were very close or below the normal threshold 
(550 pg/mL) with the exception of P2.
In patient P2 the GDF-15 concentration already decreased to almost normal levels after only four months of 
treatment. For this patient the next measurement was performed after two years of treatment and a few days after 
the nucleoside treatment dose was reduced to 300 mg/Kg (and remained at this dose) because of diarrhea, and 
at this point GDF-15 was increased (to half the baseline level). Three months later, GDF-15 had almost returned 
to normal levels in P2. We do not know when exactly the increase in GDF-15 occurred and whether it happened 
before or during the few days interval between the change of dose and the measurement.
When we analysed FGF-21 levels, we found significant differences between the intervals (p = 0.01) although 































1 F 23 m <P3 N N N p.Lys202del/p.Asp177Tyr 25% N 1183 15.000 1373
2 M 30 m <P3 N Y NGT p.His121Asn/p.His12Asn 50% Y 538 4608 402
3 M 17 m P3 N Y NGT p.Tyr208Cys/p.Arg130Trp 15% N 148 14756 3013
4 M 15 m <P3 N Y N p.His121Asn/p.Arg192Lys 13% N 284 ND ND
5 M 13 m <P3 N Y NGT p.Thr108Met/Leu215Pro ND ND 872 21641 4088
6 M 13 m <P3 N Y NGT p.Thr108Met/Leu215Pro ND ND 949 22767 3244
7 M 13 m <P3 N N N p.Lys85*/p.Pro154Leu ND ND 921 27066 7531
8 M 24 m ND ND ND ND p.Thr108Met/p.Thr108Met ND ND 285 4597 ND
9 M 31 m ND ND ND ND p.Thr108Met/p.Thr108Met 8% ND 626 6825 ND
10 F 3 y P3 Y Y NGT p.Asn58Ser/p.Asn58Ser ND ND 1789 4797 809
11 M 3 y P50 Y N N p.Asn58Ser/p.Asn58Ser ND ND 1036 2641 398
12 F 2 y P50 Y N N p.His121Asn/p.Arg183Trp ND ND 460 3686 786
13 F 2 y P50 Y N N p.His121Asn/p.Arg183Trp ND ND 945 3841 471
14 M 3 y P3 N Y N p.His121Asn/p.Arg183Trp ND ND 184 5006 1057





16 F  > 12 y 13.86 Y Y N p.Thr108Met/p.Thr108Met 17% Y 2435 2423 666
17 M 50 y 27.7 Y Y N p.Lys202del/p.Lys202del 66% Y 357 1529 252
18 F 30 y 27.12 Y Y N p.Lys202del/p.Lys202del 60% Y 294 1695 353
19 F 20 y 17.79 Y Y Y p.Thr108Met/p.Thr108Met 39% Y 303 2439 197
20 F 60 y 26.01 Y Y N p.Lys202del/p.Lys202del ND ND 647 2483 897
21 M 30 y 23.7 Y N N p.Lys202del/p.Lys202del ND Y 350 1640 185
22 F 5 y 26.17 Y Y N p.Thr108Met/p.Thr108Met ND Y 548 2149 943
23 F 30 y ND Y Y N p.Thr108Met/p.Thr108Met 53% Y 233 1261 190
24 F 20 y 20,5 Y Y GT p.Lys202del/p.Ala420Val ND ND 1142 1979 179
25 F 50 Y 28,7 Y Y N p.Lys202del/p.Lys202del ND Y 405 ND ND
26 F 14 Y 24,5 Y Y N p.Thr108Met/p.Thr108Met 19% Y 425 ND ND
Table 1. Clinical, biochemical and molecular characteristics of patients, before treatment. BMI, body-mass 
index; CK, creatine kinase; F, female; GDF-15, differentiation growth factor 15; M, male; m, months; ND, not 
determined; NGT, nasogastric tube; N, No; P, percentile; PEG, percutaneous endoscopic gastrostomy; y, years; 
Y, yes.
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ID 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
AGE OF ONSET




23 m 30 m 17 m 15 m 13 m 13 m 13 m 24 m 31 m 36 m 36 m 24 m 24 m 36 m 6 y
27 m 10 y 30 m 2.5 y 15 m 15 m 14 m 33 m 6 y 14 y 12 y 3 y 3 y 7 y 9 y
5 y 13 y 7 y 7 y 21 m 21 m 24 m 3 y 7 y 16 y 13 y 5 y 5 y 9 y 10 y
400 300 400 400 400 400 400 400 400 400 400 400 400 400 400
CK
BASAL 1183 538 148 284 872 940 921 285 626 1789 759 460 945 184 742
0–6 Months ND 316 ND ND 649 561 275 133 175 235 243 606 857 164 269
6–12 Months 114 ND 68 132 ND ND 164 130 165 273 290 173 87 111 195
12–24 Months 55 712 ND 116 ND ND ND ND ND ND ND ND ND ND ND
>24 Months 87 285 ND 61 ND ND ND ND ND ND ND ND ND ND ND
GDF-15 (pg/mL)
BASAL 15000 4608 14756 ND 21641 22767 27066 ND ND 4797 2641 3686 3841 5006 2781
0–6 Months 1200 762 ND ND 6628 2174 588 4597 6825 4753 3105 ND 2635 5180 2249
6–12 Months 497 ND 5093 2021 ND ND ND 396 369 ND ND 341 330 440 345
12–24 Months 392 2084 594 255 ND ND ND ND ND ND ND ND ND ND ND
>24 Months 288 631 ND 284 ND ND ND ND ND ND ND ND ND ND ND
FGF-21 (pg/mL)
BASAL 1373 402 3013 ND 4088 3245 7531 ND ND 809 398 786 471 1057 595
0–6 Months 72 228 ND ND 1445 776 208 583 743 769 1090 ND 351 1077 417
6–12 Months 31 ND 2170 415 ND ND ND ND ND ND ND 42 <LOQ <LOQ 34
12–24 Months 30 689 603 51 ND ND ND ND ND ND ND ND ND ND ND
>24 Months 37 134 ND 100 ND ND ND ND ND ND ND ND ND ND ND
BMI
BASAL <P3 <P3 P3 P1 13,2 13,5 12,7 ND ND 15,3 20,2 13,5 16 11,5 10,5
0–6 Months ND 9.6 ND ND 12,8 13,2 12,9 ND ND 16,1 19,05 15,02 15,08 11 10,7
6–12 Months 17.2 ND 16.02 12.75 ND ND ND ND ND ND ND ND ND ND ND
12–24 Months 16.3 20 ND ND ND ND ND ND ND ND ND ND ND ND ND
>24 Months 14.9 25.3 ND ND ND ND ND ND ND ND ND ND ND ND ND
6MWT
BASAL 0 ND ND ND ND ND ND ND 420 75 342 250 272 0 307
0–6 Months 150 ND ND ND ND ND ND ND 531 350 354 ND ND ND 364
6–12 Months 250 ND ND ND ND ND ND ND 512 379 375 394 368 15 ND
12–24 Months 391 ND ND ND ND ND ND ND ND ND ND ND ND ND ND
>24 Months 477 ND ND ND ND ND ND ND ND ND ND ND ND ND ND
EK2
BASAL ND 26 30 28 ND ND ND ND ND ND ND ND ND ND ND
0–6 Months ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
6–12 Months ND 9 21 14 ND ND ND ND ND ND ND ND ND ND ND
12–24 Months ND ND ND 12 ND ND ND ND ND ND ND ND ND ND ND
>24 Months ND 13 ND 11 ND ND ND ND ND ND ND ND ND ND ND
NSAA
BASAL 4 ND ND ND ND ND ND 20 27 ND ND ND ND ND ND
0–6 Months 6 ND ND ND ND ND ND ND 33 ND ND ND ND ND ND
6–12 Months 20 ND ND ND ND ND ND 31 33 ND ND ND ND ND ND
12–24 Months 26 ND ND ND ND ND ND ND ND ND ND ND ND ND ND
>24 Months ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
HMFS
BASAL ND ND ND ND ND ND ND ND ND 21 35 38 38 17 38
0–6 Months ND ND ND ND ND ND ND ND ND 30 33 ND ND ND 39
6–12 Months ND ND ND ND ND ND ND ND ND 36 37 39 39 23 ND
12–24 Months ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
>24 Months ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
HMFSE
BASAL ND ND ND ND ND ND ND ND ND 26 51 51 53 19 62
0–6 Months ND ND ND ND ND ND ND ND ND 48 49 ND ND ND 65
6–12 Months ND ND ND ND ND ND ND ND ND 57 55 65 65 27 ND
12–24 Months ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
>24 Months ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
CHOP INTEND
BASAL ND ND ND ND 42 45 17 ND ND ND ND ND ND ND ND
0–6 Months ND ND ND ND 45 54 64 ND ND ND ND ND ND ND ND
6–12 Months ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
12–24 Months ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
>24 Months ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
Continued
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In the group that started treatment at an older age (>16 years-old), consisting mainly of patients with a 
late-onset phenotype, biomarker determinations spanned a longer period of time (0 to >36 months). Although 
the differences in GDF-15 levels between the different intervals were significant (Kruskal-Wallis chi-squared 
p = 0.003), levels appeared to decrease mainly during the first 12 months of treatment and then remained stable 
(Supp. Fig. 1). In contrast, there was no clear trend for FGF-21 and in some patients levels even increased with 
treatment. In this case, the difference between intervals was not significant (Supp. Fig. 1).
We calculated the rate of decline of GDF-15 and FGF-21 levels relative to the basal levels in the same time 
intervals in the paediatric and adult patients for whom we had measurements before treatment (% change at time 
T = log GDF-15 at T-log GDF-15 at T0/log GDF-15 T0 x 100). The rate of decline increased with time in group 
1 for GDF-15 (−12.5% between 0 and 6 months, −26.7% between 6 and 12 months, −26.9% between 12 and 24 
months and 32.3% after 24 months) and FGF-21 (−11.5%, −36.3%, −21.3% and −34.2% in the same intervals) 
whereas it was rather uniform in group 2 for GDF-15 (−10.3% between 0 and 6 months, −12.8% between 6 and 
12 months, −12.5% between 12 and 36 months, and −12.6% after 36 months) and for FGF-21 (−15.4%, −8.4%, 
−14% and −9.1% for the same time intervals).
Change of serum GDF-15 over time in patients that stopped treatment. Patients P25 and P26 
stopped treatment because their liver enzymes had increased. P25 received treatment for three months, then 
stopped for three months, and then took nucleosides for one more month before stopping treatment completely. 
We do not have baseline levels for P25. The first GDF-15 measurement, performed after 6 months without treat-
ment, was elevated (1833 pg/mL). One month later, GDF-15 levels had decreased to 1489 pg/mL, two months 
later (9 months after stopping the treatment completely) GDF-15 went up to 1675 pg/mL. Then they remained 
elevated (1657 pg/mL) even after 18 months of stopping the treatment when the last measurement was taken.
P26 received treatment for three months, stopped for four months, and then restarted treatment for one more 
month before stopping completely. GDF-15 levels were measured nearly three months after treatment inter-
ruption and were then mildly elevated (688 pg/ml). Then, in this patient, they remained stable over the next 
four months (including one month with treatment) to 639 pg/mL. Three months later (10 months after the first 
treatment interruption) it had risen to 818 pg/ml. From then onwards, levels continued to rise (1301 pg/mL after 
13 months of treatment interruption) to reach 1656 pg/mL at the last measurement, 16 months after treatment 
interruption.
Thus, the trend of GDF-15 in the absence of treatment appears to reflect the disease course in these two 
patients, P25 has remained clinically stable whilst P26 has a more progressive form of the disease.
The comparison between GDF-15 concentrations in treated adult patients and these two patients that stopped 
over a similar time frame (0 to 28 months) is shown in Fig. 3. While in the treated patients GDF-15 levels declined, 
in the two patients that stopped they went up or remained stable but did not lower in either case.
Clinical outcome measures and correlation analysis. We analyzed several clinical outcomes in both 
patients groups to determine whether the decline in GDF-15 was associated with clinical improvement following 
treatment. Tables 2 and 3 and Fig. 4 summarise this information.
Patients P1, P3, and P4 are the patients P5, P2, and P1 in our previous report9. They are in the early-onset and 
severe myopathy group in which the response to treatment was striking. This group of patients was defined by 
(1) onset before 24 months and (2) inability to walk, use of mechanical ventilation, or both within one year of 
onset. Without treatment, only 27.3% of patients described in the literature with such characteristics survived at 
least two years after onset (95% CI = 0.17–0.45)9. In contrast, with treatment, P1, P3, and P4 are still alive, four, 
six, and six years after disease onset respectively. One of these patients was weaned of ventilatory support and 
the two others regained the ability to walk without assistance. Patients P5, P6, and P7, not reported previously, 
also represent the most severe phenotype with early-onset and very rapid progression course. After treatment, 
they were evaluated with the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP 
INTEND) assessments, which showed a mean improvement of 13.7 points after only three months of follow-up, 
and one (P7) even reached the maximum score on the scale three months later, which indicates complete motor 
recovery after only six months of treatment.
In childhood-onset cases, when we compared the latest post-treatment value (around one year after the start 
of the treatment) to the pre-treatment value for the more frequent outcome measures used, we found a significant 
improvement in the distance walked on the 6-minutes walking test (6MWT), with a mean increase of 105.8 meters 
(p = 0.01) (Fig. 4A). We also found a significant improvement in the scores of the Hammersmith Motor Function 
ID 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
FVC (%)
BASAL ND 13 ND ND ND ND ND ND ND ND ND ND ND ND 38
0–6 Months ND ND ND ND ND ND ND ND ND 19 50 ND ND ND 66
6–12 Months ND 22 ND ND ND ND ND ND ND 35 70 ND ND 71 ND
12–24 Months ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
>24 Months ND 26 ND ND ND ND ND ND ND ND ND ND ND ND ND
Table 2. Outcome measures, Group 1 (age at treatment initiation <16 years). CK, creatine kinase; EK, Egen 
Klassifikation; HMFS, Hammersmith Motor Functional Scale; HMFSE, Hammersmith Motor Functional 
Scale Expanded; 6MWT, 6-minute walk test; m, months; ND, not determined; NSAA, North Star Ambulatory 
Assessment; y, years.
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Scale (HMFS) and the Hammersmith Motor Function Scale-Expanded HMFSE scales (Fig. 4B,C), with an aver-
age improvement of 4.3 points and 12 points respectively between the pre-treatment and last post-treatment 
determinations (p = 0.03 in both cases) (Fig. 4A). Other clinical outcome measures (Egen Klassifikation Scale 
2, EK2; North Star Ambulatory Assessment, NSAA) also reflected improvements, although without reaching 
statistical significance, when pre-treatment and post-treatment scores were compared. We did not have enough 
basal data regarding respiratory function (Forced Vital Capacity, FVC) to perform specific analyses in this group 
of patients (Fig. 4D).
ID 16 17 18 19 20 21 22 23 24
AGE OF ONSET




>12 y 50 y 30 y 20 y 60 y 36 y 5 y 30 y 20 y
30 y 58 y 59 y 31 y 74 y 60 y 35 y 46 y 57 y
34 y 62 y 62 y 34 y 75 y 60 y 36 y 46 y 60 y
320 300 400 400 400 400 350 300 400
CK (UI/l)
BASAL 2435 525 294 303 647 402 548 188 1142
0–6 Months ND ND 123 322 ND 264 107 ND 1195
6–12 Months 393 ND 258 292 105 ND 142 ND 1348
12–36 Months 330 351 108 110 ND ND ND ND ND
>36 Months 561 459 185 467 89 ND ND ND ND
GDF-15 (pg/mL)
BASAL 2423 1529 1695 2439 2483 1640 2149 1261 1980
0–6 Months ND ND ND ND 1364 1357 473 486 1052
6–12 Months ND ND ND ND 1320 ND 413 ND 1011
12–36 Months 464 782 704 1110 1099 ND ND ND ND
>36 Months 480 1137 753 783 ND ND ND ND ND
FGF-21 (pg/mL)
BASAL 666 252 353 197 897 185 943 190 179
0–6 Months ND ND ND ND 732 135 47 ND 113
6–12 Months ND ND ND ND 344 ND ND ND 155
12–36 Months 1222 944 245 915 ND ND ND ND ND
>36 Months 632 1025 421 ND ND ND ND ND ND
BMI
BASAL 13.86 27.7 27.12 17.79 26.01 23.7 26.17 ND 20,8
0–6 Months ND ND ND 19,06 25 23.6 25.4 ND 21
6–12 Months ND ND ND 21,09 27,6 ND ND ND 20,4
12–36 Months 16.06 ND 26.3 21.23 ND ND ND ND ND
>36 Months ND ND 26.9 18,63 ND ND ND ND ND
6MWT
BASAL 532 475 386 390 345 ND 368 413 225
0–6 Months ND 500 355 437 ND ND 435 515 251
6–12 Months ND ND 400 474 ND ND 450 ND 228
12–36 Months 550 435 354 369 ND ND ND ND ND
>36 Months 600 442 450 476 ND ND ND ND ND
NSAA
BASAL ND ND 26 21 29 ND 16 30 ND
0–6 Months 30 24 26 21 ND ND 25 31 ND
6–12 Months ND ND 29 23 ND ND 26 ND ND
12–36 Months 29 27 32 28 ND ND ND ND ND
>36 Months 30 ND 31 29 ND ND ND ND ND
PIM (%)
BASAL 25 40 49.9 5 59 ND 37 31 ND
0–6 Months ND ND 40.2 ND 33,9 ND 37,8 ND ND
6–12 Months 29.5 ND 53 24 47.3 ND ND ND ND
12–36 Months 21.4 38.6 49.9 ND 39,8 ND ND ND ND
>36 Months ND 28 53 27 ND ND ND ND ND
FVC (%)
BASAL 46.5 45 71.8 26 69 78 53.2 63.7 ND
0–6 Months ND 51.4 79.5 33 66,5 82.6 62 64 16
6–12 Months 50.3 ND 75 23,7 78,9 ND ND ND 17
12–36 Months 46.7 46.7 77.7 32,2 83,4 ND ND ND ND
>36 Months 50.5 43.6 72 34,8 ND ND ND ND ND
Table 3. Outcome measures, Group 2 (age at treatment initiation >16 years). ND, not determined; CK, 
creatine kinase; y, years; m, months; NA, not available, GDF-15, growth differentiation factor 15; FGF-21, 
fibroblast growth factor 21; BMI, body mass index; 6MWT, six-minute walk test; NSAA, north star ambulatory 
assessment; PIM, maximal inspiratory pressure; FVC, forced vital capacity.
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In the adult group, consisting mainly of patients with late-onset disease, the 6MWT and the FVC showed a 
significant improvement when we compared pre- and post-treatment values (p = 0.05 and p = 0.04 respectively). 
This difference became more striking when we considered the changes in FVC during the first 12 months of treat-
ment (p = 0.02). In particular, the 6MWT showed an improvement of an average of 53.2 meters after treatment 
(Fig. 4E), while the NSAA increased a mean of four points (Fig. 4F) and, more importantly, the mean FVC after 
treatment was 5% greater (Fig. 4G).
We had previously shown that mRNA and protein levels of GDF-15 and FGF-21 correlate strongly and signifi-
cantly in children with a range of mitochondrial diseases and in myogenic cell lines in which mitochondrial dam-
age was induced experimentally12. In keeping with this previous result, baseline and longitudinal concentrations 
of both factors also correlated with each other significantly in treated patients (p < 0.001; Spearman r = 0.843), 
(Fig. 4H).
When analysing group 1 and group 2 together, basal circulating GDF-15 and FGF-21 concentrations corre-
lated significantly and negatively with age-at-treatment initiation (p = 0.006, r = −0.7 and p = 0.004, r = −0.7 
respectively) and with weight expressed as BMI (p < 0.001, r = −0.8 and p = 0.024 and r = −0.5 respectively). In 
addition, basal GDF-15 concentrations correlated with the meters walked in the 6MWT (p = 0.003, r = −0.75).
Inflammatory cytokines profile in patients with TK2 deficiency. Mitochondrial diseases and, in 
particular, TK2 deficiency are often associated with local (skeletal muscle) inflammatory responses which may 
be related to muscle cell damage or necrosis12. Given that GDF-15 can be induced by various stimuli related to 
inflammation, we assessed the circulating levels of the inflammatory cytokines IL-1, IL-6, IL-8, IL-15 and TNF 
(before and after treatment) in the eight patients from group 2 with late-onset phenotype that were followed in 
hospitals in Spain. We did not observe a significant increase in the average basal levels of any of the cytokines in 
either group of patients relative to the levels in age-matched controls nor a consistent pattern of change with time 
in treated patients (Supp. Fig. 2).
Group 1 Mean SE Range
Age onset 27.1 m 3.8 13–72 m
Age treatment start 62.1 m 12.6 14–168 m
Basal GDF-15 (pg/mL) 10716 2579 2641–27066
Basal FGF-21 (pg/mL) 1981 702 402–7531
Group 2
Age onset 29.2 y 5.3 5–60 y
Age treatment start 50 y 4.3 30–74 y
Basal GDF-15 (pg/mL) 1955 149 1261–2483
Basal FGF-21 (pg/mL) 429 106 179–943
Table 4. Summary of descriptive statistics. m, months; y, years; SE, standard error of the mean.
Figure 1. Pre-treatment GDF-15 and FGF-21 serum levels are associated with disease severity. Histograms 
representing the basal (before treatment) serum levels (mean and SEM) of GDF-15, FGF-21 and creatine kinase 
(CK) in patients from Group 1 (G1), those patients from Group 1 with the early onset and the most severe 
phenotype (G1-EO) and patients in Group 2 (G2). Dotted lines represent control values.
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Discussion
In previous work, our group described the global gene expression profile of skeletal muscle from patients with 
TK2 deficiency and identified the main molecular pathways implicated in the disease including the induction of 
GDF-15 expression partly under the control of p53. In addition, we demonstrated that GDF-15 outperformed 
other diagnostic biomarkers for mitochondrial diseases and postulated that it may also serve to monitor response 
to treatment based on preliminary data of one patient with TK2 deficiency that was treated with deoxynucleotides 
replacement therapy14,15. Since then, an expanded access program has shown a favorable side-effect profile and 
clinical efficacy of dNMP and deoxynucleoside therapies in patients with TK2 deficiency, some of them included 
in this study. Without any major side effects, the therapy had striking effects on early-onset severe myopathy 
patients, considerable functional improvements in childhood-onset cases and at least stabilization in late-onset 
ones4.
Figure 2. GDF-15 levels decreased during treatment with deoxynucleosides. Development of GDF-15 (A,B) 
and FGF-21 (C,D) circulating concentrations (pg/mL) over time in group 1 (left) and group 2 (right) patients.
Figure 3. GDF-15 levels do not decrease over time in the absence of treatment. Development of serum GDF-15 
over 28 months in treated patients (black lines) from group 2 versus untreated patients (P25 and P26, red lines).
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In the present work, we have assessed GDF-15 and FGF-21 in 24 patients with TK2 deficiency that started 
deoxynucleoside therapy either in their earlier years or as adults. The objective of this study was to ascertain the 
value of GDF-15 as a prognostic and treatment response biomarker for TK2 deficiency and compare it to FGF-21.
Together, the two groups of patients we analyzed represent the majority of patients with TK2 deficiency around 
the world that are treated. In addition, they encompass the known spectrum of the disease, from patients with 
Figure 4. GDF-15 decrease was accompanied by improvement of several clinical outcome measures in treated 
patients. Development of selected functional tests for patients in group 1: 6MWT (A), HMFS (B), HMFSE 
(C), and % FVC (D) and for patients in group 2: 6MWT (E), NSAA (F), and % FVC (G) during treatment with 
deoxynucleosides. Correlation between basal levels of GDF-15 and FGF-21 in serum for group 1 (black) and 
group 2 (red) patients together (H).
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early-onset and very rapid progression that is fatal in a few years without treatment, to childhood or late-onset 
cases with variable rates of disease progression, but also with bad prognosis because of respiratory involvement.
We confirm our previous findings that GDF-15 is markedly elevated in children and adults with TK2 defi-
ciency14,15. GDF-15 levels before the start of treatment were elevated above the normal threshold value in all 
patients and on average six times higher in the paediatric patients compared to the adult patients, even more so in 
the children with early-onset and the most severe form of the disease. Similar results were obtained for FGF-21. 
Thus, both GDF-15 and FGF-21 are useful indicators of disease severity.
This was reflected in a significant and negative correlation between the basal concentration of both factors and 
the age of onset and/or treatment initiation so that the younger the children the higher the elevation of GDF-15 
and FGF-21. Furthermore, pre-treatment GDF-15 levels were negatively associated with the meters walked on the 
6MWT, one of the main indicators of motor function and also with body weight, expressed as the BMI. Thus, the 
higher the levels of GDF-15 (and FGF-21) the lower the BMI. Considering the evidence of the role of GDF-15 in 
the regulation of body weight and appetite21,  one may speculate that the dramatically increased levels of circulat-
ing GDF-15 observed in these patients may be directly contributing to the rapid loss of body weight which is an 
important component of the disease but this requires additional studies.
Our results demonstrate that in patients treated with deoxynucleosides, GDF-15 concentrations decrease fol-
lowing a significant dependence over time and therefore GDF-15 fulfills the criteria for a treatment response 
biomarker. Although a similar trend was obtained for FGF-21 the decrease was not as consistent or as marked, 
particularly for patients in group 2. In contrast to treated patients, in TK2 deficient patients without treatment 
levels of GDF-15 tended to increase over short periods of time although more natural history data on untreated 
patients are necessary. All the patients under treatment showed important beneficial effects that are maintained 
over time or, at least, the stabilization of the disease. The response to treatment was greatest in group 1 (the paedi-
atric group), but the mild motor improvements and respiratory stability shown in group 2 (the adult group) are a 
relevant clinical result as well since they show that treatment can reduce morbidity and mortality also in patients 
who started treatment in adulthood. In keeping with the extent of the clinical benefit, the rate of GDF-15 decrease 
was faster in children than in adults, in particular, in the most severe patients who are the ones that respond 
more markedly to the treatment in the form of extended survival, recovery from ventilatory support dependency, 
and regaining motor abilities. It has been recently reported that age-related metabolic changes in mice (namely 
increased deoxynucleoside catabolism and decreased anabolism with age) account, at least in part, for the limited 
efficacy of the treatment in this model8.
Both GDF-15 and FGF-21 are broad action cytokine/hormone that are altered at the same time in many dis-
ease states where they are routinely employed as diagnostic and prognostic biomarkers12,20–25. In particular, they 
are increasingly used individually or in combination as diagnostic biomarkers of mitochondrial diseases9,16,18.
In this study, we found that both GDF-15 and FGF-21 were elevated in all patients before deoxynucleoside 
treatment but that GDF-15 was more robust than FGF-21 to monitor changes over time in treated patients. 
Furthermore, GDF-15 correlated with motor function (6MWT) although this needs to be confirmed in a larger 
group of treated patients.
Our previous transcriptomic data of skeletal muscle indicates that p53 is the key regulator in a network of 
genes which are coordinately activated in response to TK2 deficiency leading to inflammation, activation of mus-
cle cell death by apoptosis and induction of GDF-15 in muscle and serum. p53 plays a fundamental role in the 
control of the cell cycle, DNA repair and apoptosis in the nucleus and in mitochondria. Under certain condi-
tions such as increased oxidative stress, p53 translocates to mitochondria to repair and/or promote replication of 
mtDNA14. Thus, our hypothesis is that mitochondrial DNA depletion due to TK2 mutations lead to activation of 
p53 which binds to the promoter region of GDF-15 inducing its expression and release by affected tissues.
Both GDF-15 and FGF-21 have a role in inflammation, for example, in pancreas, heart and adipose tis-
sue13,21–23. Our data show that the profile of inflammatory cytokines was not consistently altered at baseline (not 
even in the children with the most severe early-onset phenotype) indicating that the elevated levels of GDF-15 and 
FGF-21 are not secondary to systemic inflammation. Similarly, treatment with deoxynucleosides did not result in 
a consistent pattern of change on the baseline levels of the inflammatory cytokines. However, we cannot exclude 
a contribution from local, tissue-specific, inflammation since we have previously observed over-expression of 
inflammatory markers in muscle biopsies from patients with TK2 deficiency and other mitochondrial DNA 
depletion syndromes14.
Limitations of the current study were that biochemical and clinical evaluations were performed at different 
time intervals depending on where the patients were being followed and that functional scales were not uniform 
across the cohort. This was difficult to overcome since in some cases samples had been collected retrospectively 
and not as part of a controlled study and some patients started treatment several years ago. Another important 
limitation is that we did not have the possibility to follow the levels of GDF-15 and FGF-21 in a group of untreated 
patients with TK2 deficiency in order to find out how they would change over time. TK2 deficiency is a very 
rare disease and given the severity of the phenotype and the effectiveness of deoxynucleoside treatment the vast 
majority of patients worldwide are being treated.
In conclusion, we propose that GDF-15 may be a potential biomarker of disease severity and response to treat-
ment with deoxynucleosides in patients with TK2 deficiency and potentially also in other forms of mitochondrial 
DNA depletion and deletion syndromes where this treatment may also be beneficial.
Materials and Methods
Study design. We determined circulating GDF-15 and FGF-21 at baseline and at various time points in a 
group of 26 patients with mutations in TK2 treated with deoxynucleosides. We examined the rate of change over 
time, and correlated its basal and follow-up levels with various clinical parameters related to disease severity and 
response to treatment.
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Standard protocol approvals, registrations, and patient consents. This study was conducted in 
accordance with the Declaration of Helsinki and legal regulations and was approved by the Ethics and Research 
Committee of the Fundación Sant Joan de Déu. Written informed consent was obtained from all patients or their 
parents/guardians prior to enrolment.
Study population and setting. Patients were included if they had two mutations in the TK2 gene and were 
receiving treatment with deoxynucleosides. Several of these patients have been described elsewhere9 and their 
basal characteristics are detailed in Table 1 and Supplementary Table S1. Patients were followed in five Hospitals 
in Spain (Hospital 12 de Octubre, Madrid; Hospital Sant Joan de Déu, Barcelona; Hospital de la Santa Creu I Sant 
Pau, Barcelona; Hospital Virgen del Rocio, Seville and Hospital Universitario Donostia, San Sebastian) and in the 
Columbia University Medical Center (New York, USA).
Oral administration of deoxynucleosides. All patients were treated with oral doses between 300–
400 mg/Kg/day of each nucleoside (thymidine, dThd, and deoxycytidine, dCtd). Two patients (P3 and P4) started 
with nucleotides (dTMP and dCMP) and later switched to nucleosides (in a one-to-one ratio of height:weight), 
once it became clear that these are the active agents5,6. The majority of patients (n = 24) are currently being treated 
with dThd and dCtd. Two adult-onset individuals (P25 and P26) had to stop treatment because of liver enzymes 
elevation and were excluded from the main analyses.
Analytical methods. Serum samples were collected, allowed to clot, centrifuged at 1300 g for 10 minutes, 
aliquoted, and stored at −80 °C until the moment of the analysis. Long-term storage of samples at −80 °C does 
not affect GDF-15 or FGF-21 stability according to our experience and published data20.
Previously, we had compared serum (collected in serum separator tubes) and plasma samples (collected in 
EDTA, heparin lithium or heparin sodium tubes) from the same individuals and found comparable GDF-15 and 
FGF-21 levels regardless of the type of sample and collection method. We also compared different times of sample 
collection (fasting versus postprandial) and found no significant differences for either GDF-15 or FGF-21 (data 
not shown).
Quantitative sandwich ELISAs were performed using the Quantikine Human GDF-15 Immunoassay kit 
(R&D Systems, Minneapolis, USA) and the FGF-21 ELISA KIT (R&D Systems, Minneapolis, USA or Millipore, 
Massachusetts, USA) as previously described9,15. Sensitivity, intra-assay and inter-assay variances (expressed as 
CV%) are 4.39 pg/mL and 8.69 pg/mL, 2,26% and 3,43% and 5,43 and 7,5% for GDF-15 and FGF-21 respectively.
Briefly, serum samples were either diluted ¼ in the sample diluent buffer provided with the kit as recom-
mended by the manufacturer (GDF-15) or used undiluted (FGF-21). A volume of 50ul of diluted serum sample 
was added to each well and assays were performed in duplicate. A standard curve was prepared using a dilution 
series (in pg/mL) of a recombinant human GDF-15 or FGF-21 standard diluted in the sample diluent buffer pro-
vided with the kit. To determine the optical density of the preparations we used a microplate reader (Molecular 
Probes) set to 450 nm subtracting readings at 540 nm for wavelength correction. The values from each sample 
were extrapolated from a standard four-parameter logistic curve using the SoftMax software of the microplate 
reader. Final concentrations were corrected by the dilution factor.
Interleukin (IL)-1B, IL-6, IL-8, IL-15, tumor necrosis factor (TNF) and monocyte chemoattractant protein-1 
(MCP1) were quantified using a multiplex analysis system based on fluorescently labeled microspheres linked to 
specific antibodies (HCYTOMAG-60K-06, Millipore Linco Research/Millipore, Massachusetts, USA) using a 
Luminex100ISv2 instrument.
Outcome measures. Motor assessment: Patients underwent periodic motor assessments with at least one 
of the following: 6-minute walk test (6MWT); North Star Ambulatory Assessment (NSAA), which evaluates 
motor goals with a score range of 0–34 as values of minimum and maximum motor skills, respectively; Egen 
Klassifikation (EK2), which evaluates functional capacity in nonambulatory patients with a score range of 30–0 as 
values of minimum and maximum functional capacity, respectively; the Children’s Hospital of Philadelphia Infant 
Test of Neuromuscular Disorders (CHOP INTEND) used to evaluate the motor skills of infants with SMA with a 
score range from 0 to 64, with higher scores indicating better motor function; Hammersmith Motor Functional 
Scale (HFMS), which assesses the physical abilities of children with non-ambulant Spinal Muscular Atrophy, with 
a total score achievable of 40, with higher scores reflecting better physical abilities; or the Hammersmith Motor 
Functional Scale Expanded (HFMSE), which contains additional items for the ambulant population, with a total 
score achievable of 66.
Respiratory evaluation: We measured forced vital capacity (FVC) and maximal inspiratory pressure (MIP) in 
an upright position in compliant patients.
Statistical analysis. Descriptive statistics and correlation analyses were performed using R version 3.2 and 
GraphPad PRISM version 8.1.2 A. A p-value of < 0.05 was considered statistically significant. Spearman’s cor-
relation was used to determine the relationship between numerical variables, and a paired non-parametric test 
was used to compare variables at two times (pre- versus post-treatment) for the same patient. Repeated measures 
mixed linear models were used to determine whether numerical variables changed over time if data was available 
at multiple time points.
Data availability
The raw data and protocols used for this study are available from the corresponding author.
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